KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial (Q43250046)
scientific article published on 2 November 2009
Language:
(P31) (Q13442814)
(P50) (Q42564968)
(Q46221708)
(Q49251838)
(P304) 5931-5937
(P407) (Q1860)
(P433) 35
(P478) 27
(P577) Monday, November 2, 2009
(P921) (Q188874)
(Q422327)
(Q25493920)
(Q412197)
(P1433) (Q400292)
(P1476) "KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial" (language: en)
(P2093) Matthew T Seymour
Philip Chambers
Faye Elliott
Catherine L Daly
Angela M Meade
Graham Taylor
other details
description scientific article published on 2 November 2009

External Links